Podcast
MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper
Good vs Great: What Makes a Rock STAR MSL?
Summary
In this episode, Tom Caravela engages in a thoughtful discussion with Sanaz Cardoza on the nuances that differentiate good MSLs from great ones. They explore the critical role of attitude, gratitude, and perspective in achieving success. Sanaz shares insights on common mistakes MSLs make and emphasizes the importance of proactivity and mentorship. They delve into the art of being an MSL, highlighting the significance of emotional intelligence, education, SOPs, and medical strategy. The episode wraps up with Sanaz offering advice to her younger self and reflections on building confidence in the MSL role.
My guest this week is Sanaz Cardoza, Senior Director, Field Medical at Mallinckrodt Pharmaceuticals who discusses what makes a Rock Star MSL.
Sanaz shares…
π What matters most to MSL Leaders
π What does it take to be a great MSL
π How you can separate yourself from your peers
π The art of the MSL job and what it entails
π Advice for high performing MSLs
MSL, Medical Science Liaison, emotional intelligence, mentorship, medical strategy
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
Surround to Succeed: Building a Motivational Network
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary